Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-0261 SAD Study in Healthy Volunteers
NCT07279636Phase 1Completed
- Sponsor
- AlphaMol Science
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Alpha-0261 (2 arms), sponsored by AlphaMol Science. Primary endpoint: Frequency of treatment emergent adverse events at 1 week. Started Jul 2025; status: completed.
02
Drugs
Alpha-0261
Beyond the preview
Go deeper on NCT07279636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279636.